Thursday, March 28, 2013
1:00 PM - 2:30 PM ET

Since the Supreme Court’s observation that “Congress intended statutory subject matter to ‘include anything under the sun that is made by man,’” there have been shifting tides as to the precise boundaries of patent eligibility for life science technologies. The Court addressed these issues in Mayo Collaborative Services v. Prometheus Laboratories, Inc. and will soon address patent eligibility under section 101 again in Association for Molecular Pathology v. Myriad Genetics, Inc. The Federal Circuit has likewise been active in this area and the precise rules as to what is patentable and what is not across the broad array of life sciences technologies has yet to be spelled out.

This program will provide a comprehensive overview of the history of patent eligible subject matter jurisprudence for life science technologies up through Mayo and Myriad and will also provide analysis regarding what issues have been resolved and where the law still remains murky. Also addressed will be specific types of claims across life sciences technologies and where they stand on section 101 patentability.

Educational Objectives:

• Understand the historical evolution of the doctrine of patentable subject matter, particularly as applied to life sciences technologies.
• Learn the implications of the Supreme Court’s Mayo decision and what can be expected in the upcomingMyriad case.
• Gain an understanding of the patent eligibility of a broad array of claim types, including composition and method, across life sciences technologies.

Who would benefit most from attending the program?

• In-house counsel at companies involved with pharmaceutical, biologic, or similar products.
• Practitioners who litigate or counsel companies involved with pharmaceutical or biologic products.

Program Level: Intermediate

Credit Available: This program is CLE-credit eligible.

Register now at bloombergbna.com

---

---